SCD-HeFT研究
Sudden Cardiac Death in Heart Failure Trial
Presented at
American College of Cardiology
Scientific Sessions 2004
Presented by Dr. Gust H. Bardy
SCD-HeFT
Endpoints (median 45.5 months):
All-cause mortality
SCD-HeFT
Presented at ACC Scientific Sessions 2004
2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ≤35%
Randomized, double-blind, multicenter
Conventional CHF Treatment + Placebo
Conventional CHF Treatment + ICD
Single lead implantable cardioverter defibrillator programmed for ventricular fibrillation (VF) treatment only
Treatment
Conventional CHF Treatment + Amiodarone
Antiarrhythmic agent
800 mg Week 1, 400 mg Week 2-4
Chronic therapy:
200 mg/day if <150 lbs
300 mg/day if 150-200 lbs
400 mg/day if >200 lbs
All-cause mortality at 5 years
Amiodarone vs placebo
HR 1.06, p=0.529
ICD vs placebo
HR 0.77, p=0.007
Medication use at end of follow-up included 72% ACE-inhibitors, 78% beta-blockers, 80% loop diuretics, and 55% ASA
Prior duration of CHF was 24.5 months at baseline
No difference in all-cause mortality between amiodarone and placebo arm
Mortality was lower in ICD arm vs placebo
Presented at ACC Scientific Sessions 2004
% Mortality
SCD-HeFT
Among patients with NYHA Class II or Class III CHF and reduced left ventricular ejection fraction, treatment with an implantable ICD was associated with a reduction in all-cause mortality compared with placebo, but there was no difference between amiodarone and placebo
Secondary endpoint data not yet reported
SCD-HeFT